Henry Ward, MD
Cardiovascular Disease · New Haven, CTNPI 1811970130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,673 of the $152,492 with a category attached, or 75.2%. 22 manufacturers reported payments, led by Lexicon Pharmaceuticals, Inc. at 37.6% of the total. Reporting peaked in 2019 at $72,390 and has fallen 97.9% since, to $1,556 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $554.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$57K
- Vifor Pharma, Inc.$29K
- Novartis$19K
- Lundbeck LLC$16K
- Amgen$16K
- AstraZeneca$8K
- plus $7K from 16 others
Across 1 payment — averaging $558.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$558
What the payments were for
- Speaking & faculty fees$114,67375%
- Travel & lodging$27,52618%
- Food & beverage$10,1237%
- Education$1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 58 | $57,371 |
| Vifor Pharma, Inc. | 34 | $28,883 |
| Novartis | 23 | $19,436 |
| Lundbeck LLC | 20 | $16,296 |
| Amgen | 25 | $15,779 |
| AstraZeneca | 21 | $7,862 |
| Bayer | 24 | $1,947 |
| Medtronic(2 entities) | 11 | $1,651 |
| Novo Nordisk | 14 | $913 |
| Boehringer Ingelheim | 3 | $375 |
| Merck | 9 | $372 |
| Pfizer | 10 | $277 |
| Heartflow, Inc. | 2 | $271 |
| Portola Pharmaceuticals, LLC | 3 | $268 |
| Lilly USA, LLC | 2 | $217 |
| Impulse Dynamics (USA) Inc. | 4 | $145 |
| Johnson & Johnson | 3 | $139 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$152,492 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $450,478 |
| EntrestoSacubitril/Valsartan | 152 | $215,505 |
| KerendiaFinerenone | 139 | $173,381 |
| Repatha SureclickEvolocumab | 116 | $140,791 |
| XareltoRivaroxaban | 61 | $81,994 |
| InpefaSotagliflozin | 67 | $81,263 |
| BrilintaTicagrelor | 22 | $20,966 |
| JardianceEmpagliflozin | 19 | $20,806 |
| VascepaIcosapent Ethyl | 38 | $15,680 |
| FarxigaDapagliflozin Propanediol | 13 | $12,651 |
| Icosapent Ethyl | 22 | $10,953 |
| SotalolSotalol Hcl | 277 | $7,214 |
| Metoprolol Succinate | 471 | $7,182 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $6,098 |
| Metoprolol Tartrate | 736 | $5,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $277 | $450,478385 claims |
| NovartisEntresto | $19,436 | $215,505152 claims |
| BayerKerendia | $1,947 | $173,381139 claims |
| Johnson & JohnsonXarelto | $139 | $81,99461 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $57,371 | $81,26367 claims |
| AstraZenecaBrilinta, Farxiga | $7,862 | $33,61735 claims |
| Boehringer IngelheimJardiance | $375 | $20,80619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in New Haven
- Nihar DesaiNew Haven$1.4M
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- John ForrestNew Haven$164K
- Cesia Maria Gallegos KattanNew Haven$101K
- Khurram NasirNew Haven$100K
- Tariq AhmadNew Haven$75K
- Joseph AkarNew Haven$74K
- Hyung ChunNew Haven$67K
- Eric VelazquezNew Haven$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.